Contact Us
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report 2025
Item added to cart!

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025

By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments), By Route Of Administration (Intravenous, Oral, Other Routes Of Administration), By Diagnosis (Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis), By Distribution Channel (Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics), By End User (Hospitals, Research Institutions, Homecare Settings) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size has reached to $2.1 billion in 2024

• Expected to grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%

• Growth Driver: Rising Healthcare Expenditure Driving Market Growth

• Market Trend: Breakthroughs In Immune Modulation For The Market

North America was the largest region in 2024.

What Is Covered Under Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that causes progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It results from the immune system attacking the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination issues.

The main treatment types of chronic inflammatory demyelinating polyneuropathy (CIDP) are intravenous immunoglobulin, corticosteroids, plasmapheresis, Physiotherapy, and others. Intravenous immunoglobulin (IVIg) is a blood product made from pooled human plasma that contains antibodies used to treat autoimmune conditions, immune deficiencies, and inflammatory diseases by modulating the immune system. These treatments are administered via various routes, including intravenous, oral, and others, and diagnosis typically involves electrodiagnostic testing, nerve conduction studies, electromyography (EMG), spinal fluid analysis, and other diagnostic procedures. Distribution channels for these treatments include hospitals, pharmacies, online pharmacies, and specialty clinics, with end users primarily consisting of hospitals, research institutions, and homecare settings.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and growth rate 2025 to 2029: Graph

What Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2025 And Growth Rate?

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size has grown strongly in recent years. It will grow from $2.1 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to an increasing geriatric population, improvement in treatment options, increased awareness and early diagnosis, advances in immunology and autoimmune research, and rising prevalence of autoimmune diseases.

What Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Forecast?

The chronic inflammatory demyelinating polyneuropathy (CIDP) market size is expected to see strong growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to an aging global population, a growing focus on rare diseases and autoimmune disorders, improved access to healthcare, patient advocacy and awareness campaigns, and improved healthcare infrastructure. Major trends in the forecast period include increasing prevalence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment options, growing research and development activities, emergence of biosimilar therapies, and development of personalized medicine approaches.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. neurology by increasing costs for intravenous immunoglobulin (IVIG) therapies and nerve conduction study equipment imported from Austria and Japan, potentially worsening disability outcomes and raising neuromuscular specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmented?

1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments

2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration

3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis

4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics

5) By End User: Hospitals, Research Institutions, Homecare Settings

Subsegments:

1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy

2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids

3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis

4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy

5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies

What Is Driving The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market? Rising Healthcare Expenditure Driving Market Growth

The increasing healthcare expenditure is expected to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market going forward. Rising healthcare expenditure is driven by increased investments in medical infrastructure, growing demand for advanced treatments, expanded insurance coverage, and government efforts to enhance healthcare accessibility. High healthcare expenditure enhances access to advanced treatments, early diagnosis, and better management of CIDP, improving patient outcomes and quality of life. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) industry.

Who Are The Major Players In The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.

What Are The Key Trends Of The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market? Breakthroughs In Immune Modulation For The Market

Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are focusing on advancements such as intravenous immunoglobulin (IVIG) therapy to enhance treatment efficacy, improve patient outcomes, and provide more targeted and efficient immune modulation for managing CIDP. Intravenous immunoglobulin (IVIG) therapy is a treatment that involves infusing concentrated antibodies from healthy donors to help modulate the immune system and reduce inflammation in autoimmune conditions. For instance, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, announced FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin (IVIG) therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval allows its use as an induction therapy, starting with an initial dose followed by maintenance doses to support long-term disease management and improve neuromuscular function.

Need data on a specific region in this market?

What Are Latest Mergers And Acquisitions In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market? Zai Lab Partners With argenx To Introduce First Subcutaneous CIDP Treatment In China

In November 2024, Zai Lab Limited, a China-based biopharma company, partnered with argenx SE to introduce VYVGART Hytrulo as the first approved subcutaneous injection for chronic inflammatory demyelinating polyneuropathy (CIDP) in China. This collaboration aims to provide a convenient, effective, and well-tolerated treatment to address unmet medical needs and enhance patient outcomes. argenx SE is a Netherlands-based biotechnology company dedicated to advancing innovative therapies for severe autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP).

What Is The Regional Outlook For The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)  Market?

The chronic inflammatory demyelinating polyneuropathy (CIDP) market consists of revenues earned by entities by providing services such as diagnostic testing, patient management, and therapeutic treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic inflammatory demyelinating polyneuropathy (CIDP) market also includes sales of plasma exchange devices, monoclonal antibodies, nerve conduction study equipment, and physical therapy aids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)  Industry?

The chronic inflammatory demyelinating polyneuropathy (cidp) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic inflammatory demyelinating polyneuropathy (cidp) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $2.27 billion
Revenue Forecast In 2034 $3.09 billion
Growth Rate CAGR of 7.9% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Characteristics

3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends And Strategies

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Analysis And Strategic Analysis Framework

5.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate Analysis

5.4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Addressable Market (TAM)

6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation

6.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous Immunoglobulin

Corticosteroids

Plasmapheresis

Physiotherapy

Other Treatments

6.2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous

Oral

Other Route of Administration

6.3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Electrodiagnostic Testing

Nerve Conduction

Electromyography (EMG)

Spinal Fluid Analysis

Other Diagnosis

6.4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Pharmacies

Online Pharmacies

Specialty Clinics

6.5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Research Institutions

Homecare Settings

6.6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral Corticosteroids

Intravenous Corticosteroids

6.7. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Plasmapheresis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Single-Exchange Plasmapheresis

Multiple-Exchange Plasmapheresis

6.8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Physiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Muscle Strengthening Exercises

Balance And Coordination Therapy

6.9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immunosuppressive Agents

Monoclonal Antibodies

7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional And Country Analysis

7.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

8.1. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

9.1. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

9.2. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

10.1. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

11.1. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

11.2. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

12.1. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

13.1. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

14.1. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

14.2. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

15.1. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

15.2. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

16.1. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

17.1. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

18.1. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

19.1. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

20.1. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

21.1. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

21.2. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

22.1. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

23.1. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

23.2. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

24.1. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

24.2. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

25.1. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

25.2. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

26.1. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

26.2. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

27.1. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

28.1. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

28.2. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

29.1. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

29.2. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape And Company Profiles

30.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Landscape

30.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Other Major And Innovative Companies

31.1. Baxter International Inc.

31.2. CSL Behring (CSL Limited)

31.3. Grifols S.A.

31.4. Sun Pharmaceutical Industries Ltd.

31.5. Mitsubishi Tanabe Pharma Corporation

31.6. Octapharma AG

31.7. Cipla Inc.

31.8. Hikma Pharmaceuticals plc

31.9. Halozyme Therapeutics

31.10. Hualan Biological Engineering Inc

31.11. argenx SE

31.12. Hovione

31.13. Nihon Pharmaceutical Co. Ltd.

31.14. Bio Products Laboratory Ltd.

31.15. AdvaCare Pharma

32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

34. Recent Developments In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

35. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market High Potential Countries, Segments and Strategies

35.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Countries Offering Most New Opportunities

35.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Segments Offering Most New Opportunities

35.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Plasmapheresis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Physiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Pfizer Inc. Financial Performance
  • Table 81: Johnson & Johnson Financial Performance
  • Table 82: Sanofi SA Financial Performance
  • Table 83: Novartis AG Financial Performance
  • Table 84: Takeda Pharmaceutical Company Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Plasmapheresis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Physiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Pfizer Inc. Financial Performance
  • Figure 81: Johnson & Johnson Financial Performance
  • Figure 82: Sanofi SA Financial Performance
  • Figure 83: Novartis AG Financial Performance
  • Figure 84: Takeda Pharmaceutical Company Limited Financial Performance

Frequently Asked Questions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that causes progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It results from the immune system attacking the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination issues. For further insights on this market, request a sample here

The market major growth driver - Rising Healthcare Expenditure Driving Market Growth. For further insights on this market, request a sample here

The chronic inflammatory demyelinating polyneuropathy (cidp) market size has grown strongly in recent years. It will grow from $2.1 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to an increasing geriatric population, improvement in treatment options, increased awareness and early diagnosis, advances in immunology and autoimmune research, and rising prevalence of autoimmune diseases. The chronic inflammatory demyelinating polyneuropathy (cidp) market size is expected to see strong growth in the next few years. It will grow to " $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to an aging global population, a growing focus on rare diseases and autoimmune disorders, improved access to healthcare, patient advocacy and awareness campaigns, and improved healthcare infrastructure. Major trends in the forecast period include increasing prevalence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment options, growing research and development activities, emergence of biosimilar therapies, and development of personalized medicine approaches. For further insights on this market, request a sample here

The chronic inflammatory demyelinating polyneuropathy (cidp)market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
5) By End User: Hospitals; Research Institutions; Homecare Settings Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies For further insights on this market,
request a sample here

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma. . For further insights on this market, request a sample here.

Major trends in this market include Breakthroughs In Immune Modulation For The Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon